🔎 Trials Near Me

ホーム › 大腸癌 › ルイジアナ州

ルイジアナ州における大腸癌の臨床試験

ルイジアナ州内の拠点で、大腸癌に関する18件の研究が参加者を募集しています。

ルイジアナ州内の都市

公式研究テキスト(英語)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  • University Medical Center New Orleans, New Orleans
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05673148

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • LSU Health Baton Rouge-North Clinic, Baton Rouge
  • Our Lady of the Lake Physician Group, Baton Rouge
  • Our Lady of The Lake, Baton Rouge
  • 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

  • Ochsner Medical Center Jefferson, New Orleans
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07551596

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  • Mary Bird Perkins Cancer Center, Baton Rouge
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06750094

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • Mary Bird Perkins Cancer Center, Baton Rouge
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  • Mary Bird Perkins Cancer Ctr, Baton Rouge
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/11更新 · NCT04929223

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

  • Clinical Study Site, New Orleans
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07228832

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Our Lady of the Lake, Baton Rouge
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Ochsner Health, New Orleans
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  • Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology, Baton Rouge
  • Willis Knighton Cancer Center, Shreveport
被験者募集中第4相
18歳以上 · 全性別 · 2026/07/07更新 · NCT06562543

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  • Ochsner Health, Jefferson
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/18更新 · NCT07094204

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Mary Bird Perkins Cancer Center, Baton Rouge
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

  • Ochsner LSU Health Monroe Medical Center, Monroe
  • LSU Health Sciences Center at Shreveport, Shreveport
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/03/31更新 · NCT07018869

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Ochsner LSU Health Monroe Medical Center, Monroe
  • LSU Health Sciences Center at Shreveport, Shreveport
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

  • Ochsner Medical Center Jefferson, New Orleans
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/09更新 · NCT06073431

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

  • Louisiana Hematology Oncology Associates LLC, Baton Rouge
  • Mary Bird Perkins Cancer Center, Baton Rouge
  • MBP Cancer Center - Baton Rouge General, Baton Rouge
  • 他1件
被験者募集中観察研究
60歳以上 · 全性別 · 2026/01/08更新 · NCT03998202

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。